

Stock Exchange Announcement no. 10/2007
8 June 2007

Coloplast has completed the divestment of its brachytherapy business

The divestment of Coloplast's brachytherapy business to Brachysales, Inc., now known as Core Oncology, Inc., has been completed on 8 June 2007 in accordance with the conditions described in Coloplast's stock exchange announcement no. 3/2007 of 20 February 2007.

The transaction includes an independent sales force as well as Coloplast's manufacturing facility in Oklahoma, USA, also known as Mills Biopharmaceuticals LLC.

The brachytherapy business is reported in the Group's income statement as net profit from discontinued operations. The transaction has an insignificant impact on Coloplast's results.

As the brachytherapy business encompassed approximately 1% of Coloplast's Group revenue, the divestment will not affect the expectations for 2006/07 or the long-term targets for 2012.

Lene Skole
Executive Vice President, CFO

Further information

Investors and financial analysts

Jørgen Fischer Ravn
Head of Investor relations
Tel. +45 3085 1308
E-mail: dkjfr@coloplast.com

Press and the media

Jens Tovborg Jensen
Head of Media relations
Tel. +45 3085 1922
E-mail: dkjto@coloplast.com

This announcement is available in a Danish and an English language version. In the event of discrepancies, the Danish version shall prevail.